Fluidigm (LAB): Bathi saben saham sajrone rolas wulan pungkasan

Standard BioTools Inc. (LAB) maintains stability through patent-protected cell analysis methods that create customer lock-in to the platform. This TTM earnings per share chart demonstrates the current balance of power among major players, where the value -0.18 captures the metric level. Revenue is based on the sale of consumables for expensive equipment, while high margins are achieved by scaling the mass production of instruments.

Net income per share (TTM) consolidates the business's total annual income, distributing it across each security to determine the actual return on equity. By analyzing changes in TTM net income per share, an investor assesses the efficiency of Standard BioTools Inc. (LAB) biopharmaceutical equipment manufacturing plants in the US and its global research centers.